8 results on '"Klein, Reinhild"'
Search Results
2. Invariant natural killer T cells are functionally impaired in patients with systemic sclerosis
- Author
-
Pecher, Ann-Christin, Kettemann, Felix, Asteriti, Elisa, Schmid, Hannes, Duerr-Stoerzer, Silke, Keppeler, Hildegard, Henes, Joerg Christoph, Klein, Reinhild, Hinterleitner, Clemens, Secker, Kathy-Ann, Schneidawind, Corina, Kanz, Lothar, and Schneidawind, Dominik
- Published
- 2019
- Full Text
- View/download PDF
3. The good and the bad of T cell cross-reactivity: challenges and opportunities for novel therapeutics in autoimmunity and cancer.
- Author
-
Gouttefangeas, Cécile, Klein, Reinhild, and Maia, Ana
- Subjects
T cells ,T cell receptors ,CROSS reactions (Immunology) ,AUTOIMMUNITY ,IMMUNE system - Abstract
T cells are main actors of the immune system with an essential role in protection against pathogens and cancer. The molecular key event involved in this absolutely central task is the interaction of membrane-bound specific T cell receptors with peptide-MHC complexes which initiates T cell priming, activation and recall, and thus controls a range of downstream functions. While textbooks teach us that the repertoire of mature T cells is highly diverse, it is clear that this diversity cannot possibly cover all potential foreign peptides that might be encountered during life. TCR cross-reactivity, i.e. the ability of a single TCR to recognise different peptides, offers the best solution to this biological challenge. Reports have shown that indeed, TCR cross-reactivity is surprisingly high. Hence, the T cell dilemma is the following: be as specific as possible to target foreign danger and spare self, while being able to react to a large spectrum of bodythreatening situations. This has major consequences for both autoimmune diseases and cancer, and significant implications for the development of T cell-based therapies. In this review, we will present essential experimental evidence of T cell cross-reactivity, implications for two opposite immune conditions, i.e. autoimmunity vs cancer, and how this can be differently exploited for immunotherapy approaches. Finally, we will discuss the tools available for predicting cross-reactivity and how improvements in this field might boost translational approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. iNKT cells can effectively inhibit IL-6 production by B cells in systemic sclerosis.
- Author
-
Einhaus, Jakob, Asteriti, Elisa, Pecher, Ann-Christin, Keppeler, Hildegard, Klein, Reinhild, Schneidawind, Corina, Henes, Joerg, and Schneidawind, Dominik
- Subjects
- *
SYSTEMIC scleroderma , *IMMUNOLOGIC memory , *B cells , *CONNECTIVE tissue diseases , *INTERLEUKIN-6 , *IMMUNE system - Abstract
Systemic sclerosis (SSc) is a connective tissue disease with poorly understood pathogenesis and limited treatment options. Patient mortality is rooted predominantly in the development of pulmonary and cardiac complications. The overactivated immune system is assumed to sustain the inflammatory signature of this autoimmune disease. Here, we investigate the potential of immunoregulatory invariant natural killer T (iNKT) cells to inhibit proinflammatory B cell responses in an in vitro model of inflammation. B cells from healthy volunteers (n = 17) and patients with SSc (n = 15) were used for functional testing upon lipopolysaccharide (LPS) stimulation in a co-culture system with third-party iNKT cells. Cytokine production was measured with antibody-based immunoassays (ELISA) and intracellular cytokine staining. iNKT cells strongly inhibited the production of proinflammatory interleukin-6 by B cells upon stimulation with LPS in both healthy volunteers and patients with SSc. In a Transwell assay, cell contact between B cells and iNKT cells proved necessary for this inhibitory effect. Similarly, blocking of CD1d on the surface of B cells abolished the immunoregulatory effect of iNKT cells on B cells. B cell subsets with higher expression of CD1d, namely unswitched memory B cells, were more susceptible to iNKT cell inhibition. Our in vitro data underline the potential of iNKT cells in the control of SSc and provide a rationale for the use of novel iNKT cell–based therapeutic strategies in the context of autoimmune diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Autoantibody reactivity in serum of patients with major depression, schizophrenia and healthy controls
- Author
-
Laske, Christoph, Zank, Meta, Klein, Reinhild, Stransky, Elke, Batra, Anil, Buchkremer, Gerhard, and Schott, Klaus
- Subjects
- *
MENTAL depression , *SERUM , *PSYCHOSES ,PSYCHIATRIC research - Abstract
Abstract: The present study assessed 25 patients with unipolar major depression and 34 patients with schizophrenia along with 50 healthy, non-psychiatric controls for the presence of serum antinuclear (ANA), smooth muscle (SMA), anti-endothelial (AEA), anti-sarcolemma (ASA), thyroid gland (TGA) and parietal cell (PCA) antibodies. In the group of patients with major depression, the frequency of elevated ANA, TGA and PCA was significantly higher than in the control group. In addition, the group of patients with schizophrenia significantly more often showed increased levels of ANA and SMA than the control group of healthy volunteers. When the two psychiatric groups were compared, PCA serum titers in major depression and SMA values in schizophrenia were significantly more frequently elevated, whereas values of AEA and ASA showed no difference. These results point towards the existence of an unspecific (auto) immune disposition or reaction in at least a subgroup of patients with major depression and schizophrenia. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
6. Autoantibodies targeting G protein-coupled receptors: An evolving history in autoimmunity. Report of the 4th international symposium.
- Author
-
Cabral-Marques, Otávio, Moll, Guido, Catar, Rusan, Preuß, Beate, Bankamp, Lukas, Pecher, Ann-Christin, Henes, Joerg, Klein, Reinhild, Kamalanathan, A.S., Akbarzadeh, Reza, van Oostveen, Wieke, Hohberger, Bettina, Endres, Matthias, Koolmoes, Bryan, Levarht, Nivine, Postma, Rudmer, van Duinen, Vincent, van Zonneveld, Anton Jan, de Vries-Bouwstra, Jeska, and Fehres, Cynthia
- Subjects
- *
G protein coupled receptors , *AUTOIMMUNE diseases , *AUTOANTIBODIES , *SYSTEMIC lupus erythematosus , *METABOLIC disorders , *AUTOIMMUNITY , *SMALL molecules - Abstract
G protein-coupled receptors (GPCR) are involved in various physiological and pathophysiological processes. Functional autoantibodies targeting GPCRs have been associated with multiple disease manifestations in this context. Here we summarize and discuss the relevant findings and concepts presented in the biennial International Meeting on autoantibodies targeting GPCRs (the 4th Symposium), held in Lübeck, Germany, 15–16 September 2022. The symposium focused on the current knowledge of these autoantibodies' role in various diseases, such as cardiovascular, renal, infectious (COVID-19), and autoimmune diseases (e.g., systemic sclerosis and systemic lupus erythematosus). Beyond their association with disease phenotypes, intense research related to the mechanistic action of these autoantibodies on immune regulation and pathogenesis has been developed, underscoring the role of autoantibodies targeting GPCRs on disease outcomes and etiopathogenesis. The observation repeatedly highlighted that autoantibodies targeting GPCRs could also be present in healthy individuals, suggesting that anti-GPCR autoantibodies play a physiologic role in modeling the course of diseases. Since numerous therapies targeting GPCRs have been developed, including small molecules and monoclonal antibodies designed for treating cancer, infections, metabolic disorders, or inflammatory conditions, anti-GPCR autoantibodies themselves can serve as therapeutic targets to reduce patients' morbidity and mortality, representing a new area for the development of novel therapeutic interventions. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Chronic graft-versus-host-disease in CD34+-humanized NSG mice is associated with human susceptibility HLA haplotypes for autoimmune disease.
- Author
-
Sonntag, Katja, Eckert, Franziska, Welker, Christian, Müller, Hartmut, Müller, Friederike, Zips, Daniel, Sipos, Bence, Klein, Reinhild, Blank, Gregor, Feuchtinger, Tobias, Schumm, Michael, Handgretinger, Rupert, and Schilbach, Karin
- Subjects
- *
GRAFT versus host disease , *CD34 antigen , *DISEASE susceptibility , *LABORATORY mice , *HAPLOTYPES , *HLA histocompatibility antigens - Abstract
Chronic graft-versus-host disease (cGVHD) is a significant hurdle to long-term hematopoietic stem-cell transplantation success. Insights into the pathogenesis and mechanistical investigations of novel therapeutic strategies are limited as appropriate animal models are missing. The immunodeficient NSG mouse – when humanized with human bone marrow, fetal liver and thymus (BLT NSG) – is prone for cGVHD, yet mainly affects the skin. In contrast, the NSG mouse humanized exclusively with CD34 + -selected, CD3 + -depleted stem cells (CD34 + NSG) has neither been described for acute nor chronic GVHD so far. This is the first report about the development of systemic autoimmune cGVHD ≥24 weeks post stem cell receipt involving lung, liver, skin, gingiva and intestine in two NSG cohorts humanized with CD34 + grafts from different donors. Affected mice presented with sclerodermatous skin, fibrotic lung, severe hepatitis, and massive dental malformation/loss. CD4 + -dominated, T H 2-biased, bulky T-cell infiltrates featured highly skewed T cell receptor (TCR) repertoires, clonal expansions, and autoreactive TCRs. In affected tissues profibrotic IL-13 and -4 dominated over T H 1 cytokines IFN-γ and TNF-α. Thus, the time point of manifestation and the phenotype match human systemic pleiotropic sclerodermatous GVHD. The CD34 + NSG-model's intrinsic deficiency of thymus, thymus-derived regulatory T cells (nTreg) and B cells emphasizes the role of the genetic polymorphism and the cytokines in the pathogenesis of cGVHD. Importantly, the only factor discriminating diseased versus non-diseased CD34 + NSG cohorts were two risk HLA haplotypes that in human mediate susceptibility for autoimmune disease (psoriasis). Thus, the CD34 + NSG model may serve as a platform for addressing issues related to the pathophysiology and treatment of human autoimmunity and chronic GVHD. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
8. Autoantibodies to serotonin in serum of patients with psychiatric disorders
- Author
-
Schott, Klaus, Schaefer, Jacques-Emmanuel, Richartz, Elke, Batra, Anil, Eusterschulte, Beate, Klein, Reinhild, Berg, Peter Alfred, Bartels, Mathias, Mann, Karl, and Buchkremer, Gerhard
- Subjects
- *
SEROTONIN , *PARANOID schizophrenia , *RHEUMATOID arthritis - Abstract
Antibodies to serotonin in serum were investigated by ELISA in patients with paranoid schizophrenia (N=27), schizoaffective psychosis (N=38), depression (N=67), Alzheimer''s disease (N=21), chronic alcoholism (N=43), rheumatoid arthritis (N=25), and multiple sclerosis (N=16), and in healthy volunteers (N=60). Increased antibody reactivity to serotonin was found in schizoaffective psychosis, chronic alcoholism, and rheumatoid arthritis. Decreased antibody reactivity to serotonin was found in multiple sclerosis and depression. These anti-serotonin antibodies belong to the class of so-called natural autoantibodies. Alterations of these natural autoantibodies could indicate a disturbance to the immune system. It is possible that these antibodies could also influence receptor function. Autoantibodies to neurotransmitters in a wide spectrum of psychiatric disorders have not previously been reported. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.